Dear friendthe market reacted very positively and then...

Dear friend
the market reacted very positively and then immediately scaled back with excess (demonstrating the intention to mask its goodness) to last month's very important news, regarding the trofinetide rights and the concession of 2591 to acadia for FX and Rett. very important news under a future partnership for the remainder of 2591 or a change of control. the concept is very simple to interpret; a big pharma like Roche (or others like it) when it decides to invest in a small company with great potential, puts the "complications" factor first in importance, rather than that of how much it will have to spend. a small company that demonstrates that it has a safe, tolerable and effective pipeline in phase 2 and no legal complications with third parties is suitable to be invested even heavily.. Pilcher with the latest agreement with Acadia has mainly freed himself from any potentially harmful constraints 2591, thus guaranteeing no legal complications to anyone who decides to join him for the foreseeable future.Having said this, let's get to the Roche discussion:Roche has invested (thrown away) a few billion from 2018 to today with the testing of Balovaptan for the autistic spectrum and to think that it had also obtained BT. today another trial is underway with RO7017773 also on the autistic spectrum apparently for complementary purposes, which also includes Prader Willi. the trial started a month before Pilcher launched the September 2021 capital increase, which was allegedly implemented to raise capital to start the fourth 2591 Prader Willi trial. this Roche trial will end at the end of 2023 and we all know what awaits us in that period. coincidences??? we will see, but in fact Roche and Neuren have the same interest and in similar times and methods.I would also like to point out that last week, Neuren changed its representative for the European patent of Prader Willi. for the Pitt and autism patent the representative has remained the same, therefore it is assumed that for Prader Willi there is a need to accelerate the European concession by requesting the accelerated procedure in three months. this aspect will also need to be verified.
following are the consultation links

https://www.hcplive.com/view/balovaptan-fails-phase-2-efficacy-endpoints-pediatric-autism

https://forpatients.roche.com/en/trials/neurodevelopmental-disorder/autism/a-12-week-placebo-controlled-study-to-investigate-the-e-88629.html

https://classic.clinicaltrials.gov/ct2/show/NCT04299464?term=bp41316&draw=1&rank=1